Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting Prelude Therapeutics to present preclinical data posters at the 2024 AACR on its oral SMARCA2 degrader, CDK9 inhibitor and next-gen CDK4/6 inhibitor

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024 First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024 Highly selective oral SMARCA2 degrader PRT7732 IND...

X5 Music Group, Fidelio Music, Pierian Recording Society, and Prelude Records Join the Naxos of America Distribution Family FRANKLIN, TN--(Marketwire - Oct 4, 2011) - Founded in Stockholm, Sweden in 2003, X5 Music (http://www.x5musicgroup.com/) has become Europe's leading digital music label. By licensing and acquiring...